関: Kienbock's disease、osteonecrosis

WordNet

remove the bones from; "bone the turkey before roasting it" (同)debone
the porous calcified substance from which bones are made (同)osseous_tissue
consisting of or made up of bone; "a bony substance"; "the bony framework of the body"
a shade of white the color of bleached bones (同)ivory, pearl, off-white
rigid connective tissue that makes up the skeleton of vertebrates (同)os
having bones as specified; "his lanky long-boned body"
having had the bones removed; "a boneless rib roast"; "a boned (or deboned) fish" (同)deboned
a percussion instrument consisting of a pair of hollow pieces of wood or bone (usually held between the thumb and fingers) that are made to click together (as by Spanish dancers) in rhythm with the dance (同)castanets, clappers, finger cymbals
the localized death of living cells (as from infection or the interruption of blood supply) (同)mortification, gangrene, sphacelus

PrepTutorEJDIC

《所有・所属》…『の』,…のものである,…に属する・《材料・要素》…『でできた』,から成る・《部分》…『の』[『中の』] ・《数量・単位・種類を表す名詞に付いて》…の・《原因・動機》…『で』,のために(because of) ・《主格関係》…『の』,による,によって・《目的格関係》…『を』,の・《同格関係》…『という』・《関係・関連》…『についての』[『の』],の点で・《抽象名詞などと共に》…の[性質をもつ] ・《『It is』+『形』+『of』+『名』+『to』 doの形で,ofの後の名詞を意味上の主語として》・《分離》…『から』・《起原・出所》…『から』[『の』](out of) ・《『名』+『of』+『a』(『an』)+『名』の形で》…のような・《『名』+『of』+『mine』(『yours, his』など独立所有格)の形で》…の…・《時》(1)《副詞句を作って》…に《形容詞句を作って》…の・《時刻》《米》…前(to,《米》before)
〈C〉骨 / 〈U〉骨を作っている物質,骨質 / 《複数形で》骨格;死骸(がい) / 〈魚など〉‘の'骨を取る
(魚など)骨を取り除いた / (衣服が)(コルセットなどで)骨で張りをつけた[ような]
壊疽(えそ)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 骨壊死症（無血管性骨壊死症） osteonecrosis avascular necrosis of bone
2. 活動的な成人における股関節痛の評価 evaluation of the active adult with hip pain
3. 閉経後の女性における骨粗鬆症の管理におけるビスホスホネート bisphosphonates in the management of osteoporosis in postmenopausal women
4. 小児癌患者の骨に関する問題 bone problems in childhood cancer patients
5. 小児における跛行の原因に関する概要 overview of the causes of limp in children

English Journal

Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells.

Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR.AbstractThe conventional view of the mode of action of bisphosphonates is that they are taken up by bone surfaces and then ingested by bone-resorbing osteoclasts, the activity of which they inhibit through their actions on the enzyme, farnesyl pyrophosphate (FPP) synthase. This model suggests that these compounds should only have effects on osteoclasts, and does not provide an explanation for their other actions, such as the epithelial abnormalities seen in osteonecrosis of the jaw, and their possible prolongation of disease-free survival in some malignancies. The present studies set out to determine whether cells other than osteoclasts are affected by bone-bound bisphosphonates. Bone slices were incubated overnight in PBS or in solutions of bisphosphonates (100μM), washed, then transferred to 96-well plates (1 slice/well). Cells from 2 cell lines were seeded onto the bone slices: Caco-2 human colorectal adenocarcinoma epithelial cells and Chinese hamster ovary (CHO) cells. Cell proliferation (cell numbers and thymidine incorporation) was assessed at 4-72h. Cell adhesion at 4h was normal on bone slices pre-treated with bisphosphonates, but there were progressive reductions in cell numbers from 48h and even greater reductions in thymidine incorporation from 24h (>90% with zoledronate at 72h). Growth inhibition was related to the clinical potency of the bisphosphonate used. There was no evidence of increased apoptosis in cells grown on bisphosphonate-coated bone, but levels of unprenylated Rap1A were increased, indicating inhibition of FPP synthase. Similar growth inhibition was observed in primary cultures of rat osteoblasts on bone, indicating that this was not specific to transformed cells. It is concluded that bisphosphonates bound to a bone surface can act on adjacent non-bone cells and inhibit their growth. This greatly widens the range of potential target cells for these drugs.
Bone.Bone.2011 Oct;49(4):710-6. Epub 2011 Jul 23.
The conventional view of the mode of action of bisphosphonates is that they are taken up by bone surfaces and then ingested by bone-resorbing osteoclasts, the activity of which they inhibit through their actions on the enzyme, farnesyl pyrophosphate (FPP) synthase. This model suggests that these com
PMID 21807133

Treatment of acute lymphoblastic leukemia in adolescents and young adults.

Brandwein JM.SourceDepartment of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Rm. 5-109, Toronto, Ontario, M5G 2M9, Canada, joseph.brandwein@uhn.on.ca.
Current oncology reports.Curr Oncol Rep.2011 Oct;13(5):371-8.
Treatment approaches for adolescents and young adults with acute lymphoblastic leukemia (ALL) have evolved considerably in the past 5-7?years. One of the major changes has been the widespread adoption of pediatric-based protocols, which appears to have significantly improved survival and probably r
PMID 21744057